Menopause

What it is

Menopause is the permanent end of menstruation, confirmed after 12 consecutive months without a period, occurring at a median age of 51 in North America — though anywhere between 40 and 58 years is considered within the normal range. Also called "the change of life," menopause marks the point at which the ovaries have permanently ceased reproductive function and hormone production. It is not a disease, but the hormonal shift it brings — primarily a sustained decline in estrogen — affects bone density, cardiovascular health, brain function, metabolism, and psychological wellbeing far beyond the reproductive system. In Canada, every woman who lives into her fifties will experience this transition, making it one of the most universal health events in women's lives.

The full transition spans three phases:

Phase	Definition	Key features
Perimenopause	Years leading up to the final period	Irregular cycles, fluctuating estrogen, onset of vasomotor symptoms
Menopause	The single point 12 months after the last period	Confirmed retrospectively
Postmenopause	All years after that point	Persistent estrogen deficiency; bone and cardiovascular risk accumulate

Menopause before age 40 is classified as premature ovarian insufficiency (POI); between 40 and 45 it is called early menopause. Both carry greater long-term health implications and warrant earlier clinical attention.

Causes and mechanism

Natural menopause follows the progressive depletion of the ovarian follicle pool that every person assigned female at birth is born with. As viable follicles diminish, granulosa cell activity falls, and estradiol, inhibin, and anti-Müllerian hormone levels all decline. The pituitary responds by releasing more follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in an attempt to stimulate the ovaries — but eventually follicular activity ceases entirely and hormone production stops.

Induced menopause follows a different path:

• Surgical menopause — bilateral oophorectomy (removal of both ovaries) causes immediate, abrupt menopause regardless of age, often producing more severe symptoms than the gradual natural transition.
• Medical menopause — chemotherapy and pelvic radiation can damage ovarian tissue and trigger menopause; whether this is permanent depends on the patient's age and treatment intensity.

Several factors influence the timing of natural menopause. Genetics is the strongest predictor — a mother's age at menopause is the best guide. Smoking is associated with earlier menopause by 1 to 2 years. Very low body weight and prior ovarian surgery also shift timing earlier.

Symptoms and diagnosis

Symptoms result primarily from estrogen and progesterone deficiency and vary considerably between individuals.

Vasomotor symptoms — hot flashes and night sweats — are the most common, affecting up to 80% of women. Hot flashes are sudden waves of heat, flushing, and sweating; night sweats are drenching episodes during sleep that frequently fragment sleep quality.

Genitourinary syndrome of menopause (GSM) encompasses vaginal dryness, painful intercourse (dyspareunia), urinary urgency, increased frequency, and recurrent urinary tract infections. Unlike vasomotor symptoms, GSM is progressive and worsens without treatment.

Psychological and cognitive symptoms include mood changes, irritability, low mood, anxiety, brain fog, and difficulty concentrating — compounded by sleep disruption from night sweats.

Physical changes include weight gain with a shift toward central fat distribution, reduced muscle mass, skin and hair dryness and thinning, and joint aches.

Long-term risks of sustained estrogen deficiency include accelerated bone loss (with osteoporosis risk peaking in the first 5 to 10 years postmenopause) and increased cardiovascular disease risk as estrogen's vascular-protective effects are lost.

Diagnosis in Canada: In women over 45 with irregular periods and typical symptoms, menopause is a clinical diagnosis — FSH and estradiol testing are not routinely required. In women under 45, hormone testing is recommended to confirm ovarian failure, since early menopause carries greater health implications and warrants earlier intervention. LifeLabs and Dynacare both offer FSH and estradiol panels on physician requisition across most provinces.

Treatment options

Treatment goals are to relieve symptoms and protect long-term bone and cardiovascular health.

Hormone therapy (HT) is the most effective treatment for menopausal symptoms. It replaces the estrogen — and, where needed, progesterone — that the ovaries no longer produce. Transdermal estrogen (patches, gels, sprays) is generally preferred over oral tablets because it carries a lower venous thromboembolism risk. Women with a uterus require combined therapy (estrogen plus a progestogen) to protect the endometrial lining. Micronized progesterone appears to carry a lower breast cancer risk than older synthetic progestogens. HT also reduces bone loss and may reduce cardiovascular risk when started within 10 years of menopause or before age 60 — the so-called "timing hypothesis" or "window of opportunity." The decision to use HT should be individualized based on symptom severity, age, health history, and personal preference, and reviewed regularly with a clinician.

Non-hormonal options for vasomotor symptoms:

• Fezolinetant — a neurokinin B receptor antagonist that targets the hypothalamic pathway driving hot flashes; approved specifically for moderate-to-severe vasomotor symptoms.
• SNRIs (venlafaxine, desvenlafaxine) — moderate efficacy for hot flashes.
• Gabapentin — particularly useful for night sweats.
• Clonidine — modest effect on hot flash frequency.

For GSM: Low-dose local vaginal estrogen is highly effective and considered safe even for women who cannot use systemic HT.

Lifestyle measures: Weight-bearing exercise, adequate calcium and vitamin D intake, and cardiovascular exercise support bone and heart health. Avoiding common hot flash triggers — caffeine, alcohol, spicy foods, and hot environments — can reduce symptom burden for some women.

In Canada, coverage for HT and non-hormonal options varies by province. Ontario's ODB, BC PharmaCare, and Alberta's provincial drug benefit programs cover select formulations; patients should confirm coverage with their pharmacist. Virtual menopause care is available through several Canadian platforms including Felix, Cleo, Maple, Phoenix, and others, which can help patients in underserved areas access specialist-informed prescribing.

When to see a clinician in Canada

Seek care if hot flashes, night sweats, or sleep disruption are meaningfully affecting daily function; if vaginal dryness or painful intercourse has developed; or if mood changes, anxiety, or low mood have emerged around the time of the transition. Women under 45 whose periods have stopped or become very irregular should be assessed promptly — early menopause warrants hormone testing and earlier HT to protect bones and cardiovascular health. Any postmenopausal bleeding (bleeding after the 12-month amenorrhea window) requires urgent evaluation to rule out endometrial pathology.

The Society of Obstetricians and Gynaecologists of Canada (SOGC) supports individualized, informed decision-making about HT and encourages clinicians to move beyond the risk-only framing that followed the 2002 Women's Health Initiative study.

Limitations and open questions

Research is still emerging on several fronts. The long-term cardiovascular effects of different HT formulations and routes of administration are not fully characterized, particularly for women who start therapy more than 10 years after menopause. The optimal duration of HT use has not been established — current guidance recommends the lowest effective dose for the shortest time that meets treatment goals, but evidence on extended use beyond 10 years is limited. The relationship between HT and breast cancer risk remains nuanced: risk varies by formulation, duration, and individual baseline risk, and absolute risk differences are small for most women. Health Canada has not yet issued updated national guidance that fully reflects the post-WHI evidence reassessment, meaning some provincial formularies and prescribing practices lag behind current international consensus from The Menopause Society and the Endocrine Society. The role of testosterone therapy for menopausal symptoms — particularly low libido — is an active area of research, but standardized dosing and long-term safety data in women remain incomplete.